Improving Access to Novel Agents for Children with Cancer - Chard Oncology Lecture
Objectives and Disclosures
Participants will be able to:
- Differentiate adult vs. pediatric cancer drug development.
- Analyze metrics related to barriers faced in pediatric cancer drug development.
- Synthesize some of the approaches being taken to accelerate pediatric cancer drug development.
Seattle Children’s CME Planners disclose they have no relevant financial relationships. Speaker discloses he is a member of the scientific advisory board for the following companies: EMD Serono; InhibRx; Jazz; Merck; OGD2 Pharma. Relationships have been reviewed by the Program Chair and do not pose a conflict of interest for this activity’s content. Off-label use of medications will be discussed.
Steven DuBois, MD, MS
Professor of Pediatrics, Harvard Medical School Director, Experimental Therapeutics, Senior Physician, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
CME Credit
Seattle Children’s is accredited by the Washington State Medical Association CME Accreditation Committee to sponsor continuing medical education for physicians.
Seattle Children’s designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 1 hour of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Videos are available for only one year after posting.
If you wish to receive Category I CME credit for viewing this Provider Grand Rounds session, please complete the evaluation form. Upon completion of the form you will receive an auto-reply email that will serve as the only confirmation of your CME credit. Please keep the email for your records.
Provider News
The monthly Provider News email provides updates for healthcare professionals about programs and services at Seattle Children’s.
Want to receive Provider News via email? Subscribe now.